New institutional accounts ordering LYMPHIR increased 78% quarter over quarter

LYMPHIR's near-universal payer coverage expands market access

Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million

CRANFORD, N.J., Aug. 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supporting the product's commercial launch.